CD274 and non-small cell lung carcinoma: So PD-L1 immunohistochemistry helps in optimizing the treatment, avoiding unnecessary exposure of patients to the toxic effects of the drugs that are ineffective and expensive in non-expressing tumors, and is also a prognostic biomarker in non-small cell carcinomas.